It is widely known that adjuvant treatment with aromatase inhibitors (AI) for 5 years in oestrogen receptor and/or progesterone receptor-positive BC increases disease-free survival (DFS) and overall survival (OS) [4, 5]. The gene discussed is CYP19A1; the disease is breast cancer.